Search
Clostridium tetani toxoid antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10583ApprovedInvestigationalClostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. … The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium sulfate filtration and precipation.
Mixtures: 3 ANTIGEN, Repevax Injektionssuspension in einer FertigspritzeProducts: TETAVAX single dose, suspension for injection in a prefilled syringe, T-VAC 0,5 ML IM ENJEKSIYON IÇIN SÜSPANSIYON IÇEREN AMPULOxygen
go.drugbank.com/drugs/DB09140ApprovedInvestigationalVet approvedTreatment with oxygen serves to increase blood oxygen levels and also exerts a secondary effect of decreasing blood flow resistance in the diseased lung, leading to decreased cardiovascular workload in … an attempt to oxygenate the lungs.
Mixtures: Co-NE-O2-N2 Mixture, Oxygen In Helium MixProducts: N/A, Oxygen Size EDupilumab
go.drugbank.com/drugs/DB12159ApprovedInvestigational[L7186] Dupilumab is commonly marketed as Dupixent, which is available as a formulation for subcutaneous injection. It was first approved by the FDA in 2017. … Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways.
Categories: Interleukin-4 Receptor alpha Antagonist, Interleukin 4 Receptor alpha AntagonistsProducts: DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 300 mg/2ml, DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14mlHyaluronidase
go.drugbank.com/drugs/DB14740ApprovedInvestigational[A199026] Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue. … [A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338]
Products: POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION PARA ADMINISTRACIÓN OFTALMICA, HYLASE® DESSAU 150 IUGanirelix
go.drugbank.com/drugs/DB06785ApprovedInvestigationalGanirelix is a synthetic decapeptide and a competitive gonadotropin-releasing hormone (GnRH) antagonist. Derived from endogenous GnRH, ganirelix has amino acid substitutions. … [L43045] The first case of pregnancy achieved after the use of ganirelix in an assisted reproduction program was reported in 1998.[A252195] Ganirelix was first approved by the FDA on July 29, 1999.
Products: NOVOLEX 0.25 MG/0.5 ML SOLUCIÓN INYECTABLE EN JERINGA PRECARGADA, Ganirelix Astro 0,25 mg/0,5 ml Injektionslösung in einer FertigspritzeLow affinity immunoglobulin gamma Fc region receptor II-a
go.drugbank.com/bio_entities/BE0002098TargetHumansBinds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens
Polypeptides: Low affinity immunoglobulin gamma Fc region receptor II-aSynonyms: FcRII-a, Fc-gamma RII-aTransient receptor potential cation channel subfamily A member 1
go.drugbank.com/bio_entities/BE0001122TargetHumansHas a central role in the pain response to endogenous inflammatory mediators, such as bradykinin and to a diverse array of irritants. … Has a relatively high Ca(2+) selectivity, with a preference for divalent over monovalent cations (Ca(2+) > Ba(2+) > Mg(2+) > NH4(+) > Li(+) > K(+)), the influx of cation into the cytoplasm leads to membrane
Polypeptides: Transient receptor potential cation channel subfamily A member 1Low affinity immunoglobulin gamma Fc region receptor III-A
go.drugbank.com/bio_entities/BE0002097TargetHumansOptimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC
Polypeptides: Low affinity immunoglobulin gamma Fc region receptor III-ASynonyms: IgG Fc receptor III-ASuccinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial
go.drugbank.com/bio_entities/BE0002256TargetEnzymeHumans) and produce a new acyl-CoA. … Catalyzes the first, rate-limiting step of ketone body utilization in extrahepatic tissues, by transferring coenzyme A (CoA) from a donor thiolester species (succinyl-CoA) to an acceptor carboxylate (acetoacetate
Polypeptides: Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrialNKG2-A/NKG2-B type II integral membrane protein
go.drugbank.com/bio_entities/BE0010560TargetHumansDominantly counteracts T cell receptor signaling on a subset of memory/effector CD8-positive T cells as part of an antigen-driven response to avoid autoimmunity (PubMed:12387742). … In HLA-E-rich tumor microenvironment, acts as an immune inhibitory checkpoint and may contribute to progressive loss of effector functions of NK cells and tumor-specific T cells, a state known as cell
Polypeptides: NKG2-A/NKG2-B type II integral membrane proteinSynonyms: NK cell receptor A, NKG2-A/B-activating NK receptor